New cancer pill targets Hard-to-Treat tumors in early trial
NCT ID NCT07197554
Summary
This early-stage trial is testing a new oral medication called ST-01156 in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see how the body processes the drug. Researchers will also look for early signs that the drug might help control specific cancers, including liver, bile duct, and Ewing sarcoma.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hoag Memorial Hospital
RECRUITINGNewport Beach, California, 92263, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mass General Brigham Cancer Institute
NOT_YET_RECRUITINGBoston, Massachusetts, 02114, United States
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The City of Hope National Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.